The third CEO chair he's sat in. The third time he's argued that healthcare's problems live in the spaces between the players, not the players themselves.
There is a kind of executive who collects companies the way other people collect frequent flyer miles, and there is a kind who collects problems. Joe Murad is the second kind. The companies just happen to come with them.
The current problem sits at 100 Montgomery Street in San Francisco. It is called Vida Health, it serves roughly 620 employees and an annual revenue line around $110 million, and as of November 2023 it is Murad's to run. He arrived alongside a $28.5 million financing round, succeeding the founder-CEO Stephanie Tilenius after her nine-year tenure. The press release used the standard language about scaling, momentum, and growth. Murad, in interviews afterward, used different language.
He talked about pathways. Specifically, he talked about Vida's clinical model being something that could be layered, mixed, and matched to fit a person rather than a category. The verb he kept returning to was not disrupt. It was fit.
That is unusual phrasing for a sector that prefers its rhetoric in the key of revolution. Murad has been in digital health long enough to know the genre conventions, and long enough to ignore them. Twenty-plus years compresses opinions. The opinions get smaller and sharper and harder to dislodge.
Before Vida there was WithMe Health, the personalized pharmacy benefits company he ran as founding CEO starting in 2019. Before WithMe there was PokitDok, the platform-as-a-service company he led through acquisition by Change Healthcare. Before that there was Extend Health, where he served as chief operating officer. Before Extend there was eHealth, where he ran business development in the company's early days. Earlier still, leadership roles at Willis Towers Watson. The thread connecting all of it is benefits, brokers, and the strange middle layer of American healthcare that nobody outside it can quite name.
That middle layer is where Murad lives. He has never run a hospital. He has never been a clinician. He has spent his career inside the connective tissue: the part where employers meet plans meet pharmacies meet patients, and where most of the waste hides.
Financing announced concurrent with Murad's CEO appointment.
Across multiple venture rounds since Vida's founding.
A virtual care platform built around outcomes guarantees.
From eHealth's early days to Vida's virtual cardiometabolic clinic.
I believe in Vida's mission to increase access to innovative treatments that improve patient outcomes at a lower cost. - Joe Murad, on accepting the Vida CEO role
Or: why a benefits guy ended up running a virtual clinic.
The PokitDok years are the ones most people remember. The company was a platform play in the literal sense: APIs that let other healthcare software talk to each other. Eligibility checks, claims, identity. The unromantic plumbing. Murad ran it as President and CEO until 2018, when Change Healthcare acquired the company. The deal landed in the era when interoperability went from cocktail-party word to legislative deadline, and PokitDok's plumbing turned out to matter.
He did not stay at Change. He left to start over, this time at WithMe Health. The pitch there was personalized pharmacy benefits, which sounds like a tagline and is in practice an argument that PBMs - the pharmacy benefit managers who decide which drugs get covered and at what price - are doing the math wrong. WithMe's case was that medication guidance should be human-scaled rather than formulary-scaled. He built the company from founding CEO through scale.
The pattern, if you squint, is that Murad chooses companies that sit in adjacency to a giant entrenched system and propose to make it slightly less stupid. PBMs. Claims clearinghouses. Now: chronic care delivered through a phone, with a coach on the other end, with prescribing rights for GLP-1s when the case calls for them, and with the unusual contractual feature that Vida will guarantee outcomes to its enterprise customers.
That last point is the one Murad cited in interviews as the reason he took the job. Vida's performance guarantees - the contractual promise that customers only pay if the platform delivers measurable results - are rare enough in the sector that he treated them as a draw rather than a risk. Most CEOs run from contingent pricing. Murad ran toward it.
A new drug class met an old framework: step therapy.
The drug class that reshaped the obesity conversation arrived faster than the systems built to manage it. Employers wanted them covered. Plans wanted them rationed. Patients wanted them yesterday. Vida's pitch, under Murad, was a structured step approach - try the lifestyle protocol first, layer in pharmacotherapy when the evidence calls for it, measure outcomes throughout. Conservative on the surface, aggressive in the contract: if Vida's program fails to deliver, the customer pays less.
The interesting word in that sentence is step. Murad's history is full of step-shaped products: PokitDok layered APIs onto legacy systems, WithMe layered personalization onto PBM infrastructure, Vida layers human coaching, connected devices, and pharmacotherapy onto a chronic-condition population. Nothing thrown out, everything routed.
It is a worldview as much as a strategy. The American healthcare apparatus is not going to be replaced by an app. The apparatus is, however, willing to pay an outside party to make it work better. Murad has been billing himself to that customer for two decades.
Patterns, tells, and minor obsessions.
Brokers, plans, PBMs, clearinghouses. Murad's career is a tour of the intermediaries that nobody loves but everybody needs. He has never tried to be the doctor or the patient. He has built tools for the people between them.
The pull of Vida, by his own account, was the performance guarantee structure. Operators who choose contingent pricing reveal something about their confidence in the product. It is also, quietly, a competitive moat.
BA at the University of Southern California. Career built out of the Bay Area. The educational footprint is small; the operating footprint is not.
PokitDok. WithMe. Vida. Each role inherited from a stage where the technology worked and the commercial story needed an operator. Murad keeps getting handed the same kind of job.
From early eHealth to Vida's corner office.
A short collection of public remarks.
"I've always been intrigued by Vida's differentiated clinical care model with its pathways that can be layered, mixed, and matched to meet an individual's needs."
"I believe in Vida's mission to increase access to innovative treatments that improve patient outcomes at a lower cost."
"We're focused on capitalizing on the significant momentum in our market, further scaling our platform, and pursuing growth opportunities."
"I'm genuinely excited to be here. Vida has a highly committed, innovative team that's been incredibly successful."
Conversations, profiles, and primary sources.